Ketoconazole/MetyraponeHepatotoxicity and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2032卷 / 1期

关键词：

D O I：

10.1007/s40278-024-69889-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：228 / 228

相关论文

共 50 条

[21] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[22] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[23] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[24] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[25] OsimertinibLack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1949 (1) : 349 - 349
[26] Multiple drugsLymphocytopenia and off-label use: case report
Reactions Weekly, 2020, 1831 (1) : 207 - 207
[27] Omeprazole/teduglutideHypomagnesaemia and off-label use: case report
Reactions Weekly, 2021, 1837 (1) : 546 - 546
[28] RituximabLack of efficacy in off-label use: case report
Reactions Weekly, 2023, 1946 (1) : 492 - 492
[29] IvabradinePhosphenes during off-label use: case report
Reactions Weekly, 2018, 1688 (1) : 137 - 137
[30] DexamethasoneMucormycosis following off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 181 - 181

← 1 2 3 4 5 →